A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808
Description
Brief Summary
[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the
human brain.
Detailed Description
Siemens Molecular Imaging (SMI) is seeking to determine if [F-18]T808 might be useful as a
non-invasive assessment tool in the clinical evaluation of subjects with conditions
associated with tau protein aggregates, such as Alzheimer's disease. The information
collected under this exploratory study will not be used for diagnostic purposes, assessments
of the participant's response to therapy or for clinical management of the participants.
However, this exploratory study will provide baseline information on the safety,
biodistribution, and dosimetry of [F-18]T808. These data will aid in the design of future
studies of [F-18]T808 in patients with Alzheimer's disease. Overall, this study will provide
initial data that inform the development of [F-18]T808 as the first PET imaging agent for
human tau protein related pathology.
Phase
Phase 0 - exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).Inclusion and Exclusion Criteria
- Low Probability for AD Participants (Group 1)
- Participant is of any race/gender/ethnicity who has reached his or her 55th birthday at the time of informed consent.
- Participant provides written informed consent Participant is capable of complying with study procedures
- Participant is capable of communicating with study personnel
- Participant understands and speaks English
- Participant has at least an 8th Grade education
- In the Investigator"s opinion, participant has a low probability of being currently positive for AD as determined by a Mini Mental State Examination (MMSE ≥ 28) defined in APPENDIX VI of XXX protocol
- Participant has no significant hepatic or renal disease as defined by previous medical history and lab results are within the following ranges: Total bilirubin within 2x institutional upper limits of normal AST (SGOT) ≤ 2.5 x institutional upper limits of normal ALT (SGPT) ≤ 2.5 x institutional upper limits of normal Creatinine ≤ 2x institutional upper limits of normal BUN within 2x institutional upper limits of normal High Probability for AD Participants (Group 2)
- Participant is of any race/gender/ethnicity who has reached his or her 55th birthday at the time of informed consent.
- Participant or participant"s legally acceptable representative provides written informed consent Participant is capable of complying with study procedures
- Participant is capable of communicating with study personnel
- Participant understands and speaks English
- Participant has at least an 8th Grade education In the Investigator"s opinion, *participant has a high probability of being currently positive for AD that is determined by a Mini Mental State Examination (MMSE < 17) defined in APPENDIX VI of XXX protocol
- Participant has no significant hepatic or renal disease as defined by previous medical history, and lab results are within the following ranges: Total bilirubin within 2x institutional upper limits of normal AST (SGOT) ≤ 2.5 x institutional upper limits of normal ALT (SGPT) ≤ 2.5 x institutional upper limits of normal Creatinine ≤ 2x institutional upper limits of normal BUN within 2x institutional upper limits of normal
Sites
-
California
- Research Site, Los Angeles, California, 90033
- Research Site, Irvine, California, 92697
Powered by
SC CTSI